Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020)
Outlook Therapeutics (OTLK) posted quarterly Preferred Stock Liabilities of $6.5 million for Q1 2020, up 28.34% year-over-year from $5.0 million in Q2 2019, and down 22.08% quarter-over-quarter from $8.3 million in Q4 2019.
Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Preferred Stock Liabilities for 4 consecutive years, with $6.5 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Preferred Stock Liabilities rose 28.34% year-over-year to $6.5 million; the TTM figure through Mar 2020 stood at $6.5 million (up 28.34% YoY), while the FY2019 annual figure was $5.4 million, up 13.2% from the prior year.
- Preferred Stock Liabilities retreated to $6.5 million in Q1 2020 per OTLK's latest filing, from $8.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $18.3 million in Q1 2018 and bottomed at $2.9 million in Q3 2017.
- Historically, Preferred Stock Liabilities has averaged $7.5 million across 4 years, with a median of $5.2 million in 2019.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 69.91% in 2019 and fell as far as 72.46% in 2019.
- Outlook Therapeutics' Preferred Stock Liabilities stood at $17.2 million in 2017, then tumbled by 71.58% to $4.9 million in 2018, then jumped by 69.91% to $8.3 million in 2019, then slipped by 22.08% to $6.5 million in 2020.
- Business Quant data shows OTLK's Preferred Stock Liabilities at $6.5 million in Q1 2020, $8.3 million in Q4 2019, and $5.4 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 6.47 Mn |
| Dec 31, 2019 | 8.30 Mn |
| Sep 30, 2019 | 5.36 Mn |
| Jun 30, 2019 | 5.20 Mn |
| Mar 31, 2019 | 5.04 Mn |
| Dec 31, 2018 | 4.88 Mn |
| Sep 30, 2018 | 4.73 Mn |
| Jun 30, 2018 | 3.93 Mn |
| Mar 31, 2018 | 18.29 Mn |
| Dec 31, 2017 | 17.19 Mn |
| Sep 30, 2017 | 2.92 Mn |